Publications by authors named "G Della Marca"

Article Synopsis
  • Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder linked to abnormal lysine metabolism, with current diagnostics relying on unreliable biomarkers that are unstable and technically challenging to analyze.
  • A new method was developed using LC-MS/MS to quantify two alternative biomarkers (2-OPP and 6-oxoPIP) from urine and plasma samples, which showed excellent stability and linearity in testing.
  • This validated method offers a promising routine diagnostic tool for identifying and monitoring PDE in patients, potentially improving clinical outcomes.
View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) is the most common arrhythmia diagnosed at an older age. AF is associated with frailty, a condition possibly justifying the higher rate of complications and mortality in aged individuals. This study was aimed at describing the characteristics correlated to frailty in older AF subjects.

View Article and Find Full Text PDF

Background: Mucopolysaccharidosis type VI (MPS VI) is due to a deficiency of the lysosomal enzyme arylsulfatase B (ARSB) that results in multi-organ accumulation of glycosaminoglycans (GAGs). Limitations of current treatments prompted the development of a liver-directed gene therapy clinical trial for MPS VI.

Methods: We report the long-term follow-up of patients with MPS VI who discontinued enzyme replacement therapy (ERT) and received a single intravenous infusion of high-dose (6 × 10 genome copies/kg) recombinant adeno-associated virus serotype 8 (AAV8) vector expressing ARSB under the control of a liver-specific promoter (ClinicalTrials.

View Article and Find Full Text PDF

Introduction: Status Epilepticus (SE) can occur in patients without a previous epilepsy diagnosis, a condition identified as "new-onset status epilepticus" (NOSE). Treatment with benzodiazepine may fail in NOSE termination, requiring anti-seizure medication (ASM) employment. The term "established NOSE" (eNOSE) is generally employed in this context.

View Article and Find Full Text PDF

Background: Sarcopenia, defined as the loss of skeletal muscle mass, has been associated with a worse functional outcome after stroke. Measurement of temporal muscle thickness (TMT) has been introduced as an easily obtainable surrogate marker to identify patients with sarcopenia. Our study aims to investigate the correlation between pre-stroke sarcopenia, measured by TMT assessment, and functional outcome in patients treated with revascularization procedures for acute ischemic stroke.

View Article and Find Full Text PDF